AngioDynamics
ANGO
14.19
-0.23
-1.60%
AngioDynamics
US · ANGO
#3631 by market cap
14.19
-0.23
-1.60%
Live - 5344 symbols - heartbeat 203s ago
· 2026-10-08 09:19
Pre-market
13.74
-3.20%
After-hours
14.61
+2.96%
Overnight
14.50
+2.18%
- Market cap
- 596.75M
- P/E (TTM)i
- -16.13
- P/Bi
- 3.49
- EPSi
- -0.88
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on ANGO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.60, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +9.46% YoY
Margins
- Gross margin
- 54.62%
- Operating margin
- -6.97%
- Net margin
- -11.48%
Key ratios & quality
- Altman Z-Scorei
- 2.60
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 270.63M | 264.16M | 291.01M | 316.22M | 338.75M | 303.91M | 292.50M | 320.17M |
| Gross profit | 156.00M | 150.27M | 156.79M | 165.73M | 174.25M | 154.70M | 157.71M | 174.89M |
| Selling & admin expenses | 111.73M | 116.51M | 117.22M | 133.75M | 144.25M | 143.98M | 145.23M | 157.09M |
| Research & development | 28.26M | 29.68M | 36.39M | 30.74M | 29.88M | 31.51M | 26.22M | 29.45M |
| Operating profit | -1.05M | -14.04M | -14.96M | -18.22M | -18.68M | -33.84M | -24.06M | -22.33M |
| Pretax profit | -14.70M | -168.14M | -36.05M | -29.95M | -54.44M | -191.64M | -34.03M | -36.30M |
| Tax | -3.56M | -1.35M | -4.50M | -3.40M | -2.00M | -7.29M | -39.00K | 442.00K |
| Net profit | 61.34M | -166.79M | -31.55M | -26.55M | -52.44M | -184.35M | -33.99M | -36.74M |
| Basic EPS | 2 | -4 | -1 | -1 | -1 | -5 | -1 | -1 |
| Diluted EPS | 1.64 | -4.39 | -0.82 | -0.68 | -1.33 | -4.59 | -0.83 | -0.88 |
| Line item | 2025-02 | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 |
|---|---|---|---|---|---|---|
| Revenue | 72.00M | 80.16M | 75.71M | 79.43M | 78.42M | 86.61M |
| Gross profit | 38.86M | 42.22M | 41.86M | 44.78M | 41.48M | 46.77M |
| Selling & admin expenses | 35.99M | 36.67M | 40.69M | 36.86M | 38.16M | 41.39M |
| Research & development | 6.91M | 6.59M | 6.42M | 7.77M | 7.08M | 8.18M |
| Operating profit | -6.65M | -3.63M | -7.90M | -2.49M | -6.43M | -5.51M |
| Pretax profit | -4.41M | -6.11M | -10.84M | -6.36M | -8.07M | -11.04M |
| Tax | -2.00K | -60.00K | 65.00K | -5.00K | 12.00K | 370.00K |
| Net profit | -4.41M | -6.05M | -10.90M | -6.35M | -8.08M | -11.41M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.11 | -0.15 | -0.26 | -0.15 | -0.19 | -0.27 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 315.29M | 152.91M | 140.88M | 143.35M | 163.54M | 193.25M | 168.32M | 163.39M |
| Cash & ST investments | 227.64M | 54.44M | 48.16M | 28.83M | 44.62M | 76.06M | 55.89M | 53.86M |
| Inventory | 40.07M | 59.91M | 48.61M | 51.39M | 55.33M | 60.62M | 62.01M | 52.44M |
| Total assets | 836.44M | 594.21M | 561.44M | 552.75M | 532.64M | 317.67M | 280.14M | 267.16M |
| Total current liabilities | 73.30M | 51.45M | 57.58M | 74.32M | 83.83M | 91.16M | 76.20M | 74.72M |
| Short-term debt | 12.14M | 836.00K | -- | 8.78M | 14.76M | 4.73M | -- | -- |
| Long-term debt | 124.41M | 40.00M | 20.00M | 25.00M | 49.82M | -- | -- | -- |
| Total liabilities | 221,623,000.00 | 139,342,000.00 | 121,981,000.00 | 128,262,000.00 | 154,341,000.00 | 112,085,000.00 | 97,174,000.00 | 96,338,000.00 |
| Total equity | 614.82M | 454.87M | 439.46M | 424.49M | 378.30M | 205.59M | 182.97M | 170.83M |
| Retained earnings | 66.47M | -100.32M | -131.87M | -158.41M | -210.86M | -395.20M | -429.20M | -465.94M |
| Line item | 2025-02 | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 |
|---|---|---|---|---|---|---|
| Total current assets | 172.27M | 168.32M | 156.66M | 161.35M | 155.55M | 163.39M |
| Cash & ST investments | 44.76M | 55.89M | 38.76M | 41.64M | 37.81M | 53.86M |
| Inventory | 63.11M | 62.01M | 62.26M | 65.57M | 58.58M | 52.44M |
| Total assets | 285.42M | 280.14M | 265.64M | 269.68M | 260.68M | 267.16M |
| Total current liabilities | 77.97M | 76.20M | 68.28M | 71.96M | 66.07M | 74.72M |
| Short-term debt | 5.00M | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 99,545,000.00 | 97,174,000.00 | 86,787,000.00 | 93,348,000.00 | 87,321,000.00 | 96,338,000.00 |
| Total equity | 185.87M | 182.97M | 178.86M | 176.33M | 173.36M | 170.83M |
| Retained earnings | -423.15M | -429.20M | -440.10M | -446.45M | -454.53M | -465.94M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 37.44M | -14.55M | 24.09M | -7.19M | 78.00K | -28.16M | -10.13M | 3.09M |
| Depreciation & amortization | 25.88M | 23.81M | 25.92M | 29.35M | 30.87M | 27.71M | 25.80M | 22.96M |
| Free cash flow | 34.32M | -22.14M | 18.91M | -11.49M | -4.27M | -33.93M | -14.59M | 508.00K |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | 0 | 0 | -1.67M | 0 |
| Ending cash balance | 227.64M | 54.44M | 48.16M | 28.83M | 44.62M | 76.06M | 55.89M | 53.86M |
| Line item | 2025-02 | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 |
|---|---|---|---|---|---|---|
| Operating cash flow | -13.16M | 18.81M | -15.91M | 4.66M | -3.11M | 17.45M |
| Depreciation & amortization | 6.32M | 5.83M | 6.02M | 5.75M | 5.59M | 5.60M |
| Free cash flow | -14.96M | 18.03M | -16.65M | 4.24M | -4.13M | 17.04M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | 0 | 0 |
| Ending cash balance | 44.76M | 55.89M | 38.76M | 41.64M | 37.81M | 53.86M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -1.93 | -31.18 | -7.06 | -6.15 | -13.07 | -63.15 | -17.50 | -20.77 |
| ROA %i | -1.45 | -23.32 | -5.46 | -4.77 | -9.66 | -43.36 | -11.37 | -13.43 |
| ROIC %i | -1.05 | -26.60 | -6.45 | -5.60 | -11.06 | -61.11 | -17.50 | -20.77 |
| 5-year avg ROE %i | 0.68 | -5.43 | -5.19 | -6.14 | -9.37 | -24.12 | -21.38 | -24.12 |
| EBIT margin %i | -3.55 | -63.31 | -12.09 | -9.25 | -15.27 | -11.14 | -8.23 | -6.97 |
| FCF / sales %i | 12.68 | -- | 6.50 | -- | -- | -- | -- | 0.16 |
| Current ratioi | 4.30 | 2.97 | 2.45 | 1.93 | 1.95 | 2.12 | 2.21 | 2.19 |
| Quick ratioi | 3.70 | 1.72 | 1.48 | 1.15 | 1.16 | 1.38 | 1.30 | 1.37 |
| Debt / assetsi | 16.32 | 6.87 | 3.56 | 6.11 | 12.12 | 1.49 | -- | -- |
| LT debt / equityi | 20.23 | 8.79 | 4.55 | 5.89 | 13.17 | -- | -- | -- |
| Interest coveragei | -1.88 | -184.37 | -40.87 | -42.53 | -19.15 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -8.55 | -0.70 | 3.61 | 5.33 | 8.64 | 1.46 | -2.57 | -1.86 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -4.67 | -- | -20.50 | -- | -- | -- | -- | -- |
| Line item | 2025-02 | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 |
|---|---|---|---|---|---|---|
| ROE %i | -20.46 | -17.50 | -17.10 | -15.26 | -17.47 | -20.77 |
| ROA %i | -13.57 | -11.37 | -11.48 | -9.87 | -11.50 | -13.43 |
| ROIC %i | -19.97 | -17.50 | -17.10 | -15.26 | -17.47 | -20.77 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -9.26 | -8.23 | -7.73 | -6.73 | -6.52 | -6.97 |
| FCF / sales %i | -- | -- | -- | -- | 0.48 | 0.16 |
| Current ratioi | 2.21 | 2.21 | 2.29 | 2.24 | 2.35 | 2.19 |
| Quick ratioi | 1.20 | 1.30 | 1.19 | 1.20 | 1.26 | 1.37 |
| Debt / assetsi | 1.75 | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Med Device is the largest reported line at 53.16% of revenue, across 2 reported segments.
- Med Tech follows at 46.84%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Med Device53.16%
Med Tech46.84%
Region
United States85.87%
International14.13%
Quote time 2026-10-08 09:19:27 · For reference only, not investment advice and not tailored to your situation.